Protracted Continuous Infusion of 5-Fluorouracil in Combination with Doxorubicin, Vincristine, and Oral Cyclophospharnide in Advanced Breast Cancer

References

• Byfield J. E., Stanton W., Sharp T. R. Phase I-II trial of five day infused 5 fluorouracil and radiation in advanced cancer of head and neck. J Clin Oncol 1984; 2: 406–413
   PubMed Web of Science ®Google Scholar
• Calabro-Jones P. M., Byfield J. E., Ward J. F. Time dose relationship for 5 fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982; 42: 4413–1420
   PubMed Web of Science ®Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Palangie T., Bastian G., Demarcq C., Dorval T., Jouve M., Garcia-Giralt E., Vedrenne J., Fasano M., Berthau N., Coutant M., Pouillart P. Essai phase II de traitement ambulatoire par 5 fluoro-uracile administré en perfusion continue associé à la vindésine et au cyclophosphamide. Bull Cancer 1986; 3: 279–287
   Google Scholar
• Shah A., MacDonald W., Goldie J., Gudauskas G., Brisebois B. 5 FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 1985; 69: 739–742
   PubMedGoogle Scholar
• Strauss G., Schwartz J., Nickerson J., Lokich J. Continuous infusion 5-fluorouracil with or without cisplatin as third-line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 39
   Google Scholar
• Lokich J., Bothe A., Zipolit T. Constant infusion schedule for adriamycin. A phase I–II trial of a 30 days schedule by ambulatory pump delivery system. J Clin Oncol 1983; 1: 24–28
   PubMed Web of Science ®Google Scholar
• Lokich J., Corker Y. J. Phase I study of VP16–213 (etoposide) administered as continuous 5 day infusion. Cancer Treat Rep 1981; 65: 887–889
   PubMedGoogle Scholar
• Lokich J., Bern M., Anderson N., Wallach S., Moore C., Beauchamp K., Williams D. Cyclophosphamide, methotrexate, and 5 fluorouracil in a three drug admixture. Cancer 1989; 63: 822–824
   PubMed Web of Science ®Google Scholar
• Benhamed M., Garde P., Laplanche A., Renaux J., Rouesse J., Spielman M., Sancho-Garnier H. Chimiothérapie en perfusion continue ambulatoire par pompe portable: Essai de faisabilité. Bull Cancer 1985; 72: 30–36
   PubMedGoogle Scholar
• DelaFlor-Weiss E., Uziely B., Muggia F. M. Protracted drug infusions in cancer treatment: An appraisal of 5-fluorouracil, doxorubicin, and platiniums. Ann Oncol 1993; 4: 723–733
   PubMed Web of Science ®Google Scholar
• Hillcoat B. L., McCulloch P. B., Figuerrero A. T. Clinical response and plasma levels of 5 fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978; 38: 719–724
   PubMed Web of Science ®Google Scholar
• Jouve M., Palangie T., Belli L., Dorval T., Garcia-Giralt E., Beuzeboc P., Sholl S., Mosseri V., Livartowski A., Vedrenne J., Pouillart P. Cancer du sein métastasé. Chimiothérapie par doxorubicine, vindésine, cyclophosphamide et 5 FU. Interet de la perfusion continue de 5 FU. Résultats d'un essai controlé. Bull Cancer 1989; 76: 643–652
   PubMedGoogle Scholar
• Vedrenne J. B., Esteve M., Pouillart P., Guinet A. Chimiothérapie par catheters centraux tunnelisés in situ entre deux cures: Etude prospective chez 98 malades ambulatoires. Bull Cancer 1985; 72: 236–239
   PubMedGoogle Scholar
• Lokich J. J. Optimal schedule for 5 fluorouracil chemotherapy: Intermittent bolus or continuous infusion. Am J Clin Oncol 1985; 8: 445–448
   PubMed Web of Science ®Google Scholar
• Pouillart P., Palangie T., Sholl S., Belli L., Beuzeboc P., Jouve M., Dorval T., Garcia-Giralt E., Livartowsky A., Bastian G., Vedrenne J. Association de 5 fluorouracile administré en perfusion continue, de vindesine et de cyclophosphamide dans le traitement des cancers du sein métastasés: Etude de la réponse selon les sites métastatiques. Bull Cancer 1989; 76: 191–195
   Google Scholar
• Seifer P., Backer C. H., Reed M. C. Comparison of continuously infused 5 fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
   PubMed Web of Science ®Google Scholar
• Matsushima Y., Kanzawa F., Hoshi A., Shimizu E., Nomori H., Sasaki Y., Saijo N. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14: 104–107
   PubMed Web of Science ®Google Scholar
• Maybaum J., Ullman, Mandel H. G. Regulation of RNA and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980; 40: 4209–4215
   PubMed Web of Science ®Google Scholar
• Caballero C. A., Ausman R. K., Quebdeman E. J. Long tumor ambulatory continuous IV infusion of 5 FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69: 13–15
   PubMedGoogle Scholar
• Moynihan T., Hansen R., Anderson T., Quebbeman E., Beatty P., Ausman R., Ritch P., Chitambar C., Vukelich M. Continuous 5 fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11: 461–464
   PubMed Web of Science ®Google Scholar
• Berlie J., Meeus L., Meyer C., Rouesse J. Protracted continuous infusion of 5-fluorouracil among breast cancer patients. Proc Am Soc Clin Oncol 1990; 9: 40
   Google Scholar
• Chang A. Y., Most C., Pandya K. J. Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 1982; 12: 453–455
   Google Scholar
• Hansen R., Quebbeman E., Beatty P. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 1987; 10: 145–149
   PubMed Web of Science ®Google Scholar
• Huan S., Pazdur R., Singhakowinta A. Low dose continuous infusion 5-fluorouracil: Evaluation in advanced breast carcinoma. Cancer 1989; 63: 419–422
   PubMed Web of Science ®Google Scholar
• Jabboury K., Holmes F. A., Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989; 64: 793–797
   PubMed Web of Science ®Google Scholar
• Lokich J., Zipoli T. E., Moore C., Sonneborn H., Paul S., Greene R. Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer 1986; 58: 1020–1023
   PubMed Web of Science ®Google Scholar
• Fleming R. A., Milano G. A., Etienne M. C., Renee N., Thyss A., Schneider M., Demard F. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5 days) infusion. Br J Cancer 1992; 66: 668–672
   PubMed Web of Science ®Google Scholar
• Erlichman C., Fine S., Elhakim T. Plasma pharmacokinetics of 5 FU given by continuous infusion with allopurinol. Cancer Treat Rep 1986; 70: 903–904
   PubMedGoogle Scholar